Dr. Hanna is a PGY-3 Psychiatry resident at the Charles R. Drew University of Medicine and Science, based in South Los Angeles, California. His interests are in addressing the biopsychosocial determinants of health, translational psychiatry, innovative psychopharmacology, neuropsychiatry, and addiction psychiatry. Throughout his medical education and training thus far, Dr. Hanna has presented at the APA on the underpinnings of neural pathways involved in drug-induced dyskinesia, and the role of drug-delivery models crossing the blood brain barrier in limiting the impacts of levodopa-induced dyskinesia. Dr. Hanna has spent several years conducting preclinical neuropharmacology research studies at the University of California, Irvine, Leslie Lab, studying nicotinic acetylcholine receptor expression and binding via receptor autoradiography after chronic cigarette smoke extract exposure through a novel substance use animal model. He is a fellow of the UCI Excellence in Research Program, has presented his work at multiple national conferences including the APA, the Society for Neuroscience, and the AMA annual conferences, and is published in several University of California journals, including the UCI Excellence in Research Journal, and the UCI Journal of Biological Sciences. Dr. Hanna is also in Springer Nature for his clinical study on the time impact of the Goal-directed Fluid Delivery model in surgical cases. Dr. Hanna is continuing to further his clinical research interests in innovative psychopharmacology during his training at Charles R. Drew University, adopting the lens of translational psychiatry to bridge the gap in psychiatric medication management for vulnerable patient populations with functionally limiting mental illnesses.